Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Genitourinary Drugs Market

Genitourinary Drugs Market Share

Report ID: GMI11175
Published Date: Sep 2024
Report Format: PDF

Download Free Sample

Genitourinary Drugs Market Share

The market is characterized by intense competition among key players striving to expand their market presence. Leading companies are focusing on strategic initiatives such as mergers, acquisitions, and partnerships to strengthen their market position. These efforts aim to enhance their product and service offerings, expand their geographic reach, and invest in advanced technologies. Additionally, the market is witnessing the entry of new players, further intensifying the competitive landscape.

Genitourinary Drugs Market Companies

Prominent players operating in the genitourinary drugs industry are as mentioned below:

Abbott Laboratories
Allergan, Inc.
AstraZeneca Plc
Bayer AG
Bristol-Myers Squibb Co.
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline Plc
Ionis Pharmaceuticals, Inc.
Merck & Co., Inc.
Novartis AG
Pfizer, Inc.
Teva Pharmaceutical Industries Ltd

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The genitourinary drugs market was valued at USD 28.7 billion in 2023 and will grow at a 2.3% CAGR during 2024-2032 due to the increasing prevalence of genitourinary disorders.

The hormonal therapy segment in the market generated USD 13.8 billion in 2023 owing to the rising incidence of prostate cancer.

North America genitourinary drugs market is expected to grow at a 2.1% CAGR up to 2032 attributed to advanced healthcare infrastructure, and ongoing R&D activities.

Abbott Laboratories, Allergan, Inc., AstraZeneca Plc, Bayer AG, Bristol-Myers Squibb Co., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Ionis Pharmaceuticals, Inc., Merck & Co., Inc., and Novartis AG